P Vallaperta

Publications (8)17.89 Total impact

• Article: [Dyspepsia: which treatment to choose?].

  G Dobrilla, M Comberlato, A Steele, P Vallaperta
  Gastroentérologie Clinique et Biologique 02/1990; 14(1):107. · 0.80 Impact Factor
• Article: Drug treatment of functional dyspepsia. A meta-analysis of randomized controlled clinical trials.

  G Dobrilla, M Comberlato, A Steele, P Vallaperta
  [show abstract] [hide abstract]
  ABSTRACT: The results of therapeutic trials in functional dyspepsia (FD), a frequently encountered condition, are contradictory. Our aim, then, was to produce a pooled estimate, or meta-analysis, of a series of short-term randomized placebo-controlled clinical trials on the pharmacological treatment of FD with antisecretory and gastrokinetic drugs. We retrieved trials for analysis purposes by consulting computerized data bases and by scanning published reviews, Current Contents, and references cited in the individual studies. We also requested bibliographical updates from the medical departments of the manufacturers of the drugs used in the various trials. Of 74 trials retrieved by these means, 23 proved eligible for meta-analysis on the basis of six selection criteria defined a priori. Results were expressed in terms of "therapeutic success" (TS), which includes "symptom-free patients," patients with "significant improvement in symptoms," "excellent results," and so on. The differences in TS rates between the various drugs and placebo were calculated in each trial as the algebraic difference together with the respective 95% confidence interval (95% C.I.); the pooling of results of all eligible trials was done using Cochran's weighted method. With antisecretory drugs, the mean difference in TS rates versus placebo was +20% (95% C.I.: 14-24%). The therapeutic gain for the respective antisecretory agents was 25% (95% C.I.: 14-36%) in the case of pirenzepine and 18% (95% C.I.: 12-24%) in the case of H2 antagonists. Meta-analysis of trials with gastrokinetic drugs also showed superior efficacy of these agents compared with placebo, with a mean difference in TS rates of +46% (95% C.I.: 40-52%).(ABSTRACT TRUNCATED AT 250 WORDS)
  Journal of Clinical Gastroenterology 05/1989; 11(2):169-77. · 3.16 Impact Factor
• Source

  Available from: bmj.com

  Article: Influence of ulcer healing agents on ulcer relapse after discontinuation of acute treatment: a pooled estimate of controlled clinical trials.

  G Dobrilla, P Vallaperta, S Amplatz
  [show abstract] [hide abstract]
  ABSTRACT: Whether or not the incidence of ulcer relapse varies according to the drug used to produce initial healing is a controversial matter. We tackled this problem using data from 15 eligible trials from 25 published controlled trials in patients followed up for six to 12 months. Pooled estimates of differences in ulcer relapse incidence between patients initially healed with H2-antagonists and patients initially healed with non-H2-antagonist drugs were calculated. The overall incidence of relapse in patients healed with comparator drugs is 11 percentage units lower at six and 12 months, than that observed in H2-antagonist-healed patients. The confidence intervals are +/- 8% at six months and +/- 7% at 12 months. These data suggest the existence of a different effect on relapse incidence for the entire class of comparator drugs taken as a whole, compared with H2-antagonists. On considering the non-H2-antagonists singly, this conclusion holds good only in the case of tripotassium dicitrato bismuthate.
  Gut 03/1988; 29(2):181-7. · 10.11 Impact Factor
• Article: Is ethanol metabolism affected by oral administration of cimetidine and ranitidine at therapeutic doses?

  G Dobrilla, G de Pretis, L Piazzi, F Chilovi, M Comberlato, M Valentini, A Pastorino, P Vallaperta
  [show abstract] [hide abstract]
  ABSTRACT: The aim of this study was to compare the ethanol serum concentration curve, the area under the curve and subjective response after acute ingestion of ethanol (red wine, 13 degrees proof, at a dose of 0.8 g/kg of ideal weight in 6 healthy volunteers with a mean habitual alcohol intake of 20 g/day. All the subjects underwent the test a total of three times, after pre-treatment with cimetidine (400 mg X 2/day/7 days) and ranitidine (150 mg X 2/day/7 days), respectively, and after receiving no pre-treatment. The wine was taken orally within the space of 15 min, four hours after taking a standard-weight ham sandwich. Blood samples were drawn at the following times: 0, 30, 60, 90, 120, 180, 240 and 360 minutes. The plasma ethanol curve of the subjects pre-treated with cimetidine lies above that of the subjects pre-treated with ranitidine, and largely coincides with the curve obtained in those who received no pre-treatment, with the exception of the initial hour-and-a-half, when the later show a slightly higher mean plasma concentration. The differences between the three treatment groups are merely arithmetical, but not statistical, with respect to peak plasma ethanol concentrations, time elapsing before peaking, and areas under the curves. These results are at variance with some published data suggesting a significant interaction of cimetidine with the metabolism of alcohol by way of interference either with the hepatic oxidative metabolizing enzymes, or with the activity of alcohol dehydrogenase.
  Hepato-gastroenterology 03/1984; 31(1):35-7. · 0.66 Impact Factor
• Article: Skin lesions in chronic alcoholic pancreatitis.

  A Barba, W Piubello, I Vantini, S Caliari, R Cocchetto, P Vallaperta, L A Scuro, A Sapuppo, G Cavallini
  Dermatologica 06/1982; 164(5):322-6.
• Article: Discriminant analysis in the differential diagnosis of hypercalcaemia.

  V Lo Cascio, P Vallaperta, S Adami, L Cominacini, G Galvanini, I Bianchi, M Ferrari, L A Scuro
  [show abstract] [hide abstract]
  ABSTRACT: Linear discriminant analysis, a multivariate statistical procedure, applied to serum calcium, phosphate, alkaline phosphatase, bicarbonate, chloride, creatinine and tubular reabsorption of phosphate, proved to be effective in distinguishing patients with Primary Hyperparathyroidism from other hypercalcaemic patients in eithy-four retrospective cases. The application of the model to thirty-four prospective cases enabled us to separate correctly, hyperparathyroid patients from non-parathyroid hypercalcaemic patients.
  Clinical Endocrinology 05/1978; 8(4):349-56. · 3.17 Impact Factor
• Article: [Value and limitations of the blood glycoamylase test in the diagnosis of chronic pancreatic diseases].

  G Angelini, P Vallaperta, G Cavallini, R Mirachian, I Vantini, P Bovo, G Dobrilla
  Quaderni Sclavo di diagnostica clinica e di laboratorio 01/1974; 9(4):865-81.
• Article: Amylasaemai, amylasuria and secrection of pancreatic enzymes in man. Response following injection of caerulein as diagnostic test of chronic pancreatics [proceedings].

  G Dobrilla, G Cavallini, P Vallaperta, P Bovo, L Scuro
  Revista de gastroenterologia de Mexico 40(4):229-30.